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Surface Expression
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Despite playing a central role in tolerance, little is known regarding the mechanism by which intracellular CTLA-4 is shuttled
from the trans-Golgi network to the surfaces of T cells. In this context, Ras-related GTPase Rab8 plays an important role in the
intracellular transport, while we have previously shown that CTLA-4 binds to the immune cell adaptor TRIM in T cells. In this
study, we demonstrate that CTLA-4 forms a multimeric complex comprised of TRIM and related LAX that in turn binds to GTP
bound Rab8 for post-Golgi transport to the cell surface. LAX bound via its N terminus to active GTP-Rab8, as well as the cyto-
plasmic tail of CTLA-4. TRIM required LAX for binding to Rab8 in a complex. Wild-type LAX or its N terminus (residues 1 to 77)
increased CTLA-4 surface expression, whereas small interfering RNAs of Rab8 or LAX or disruption of LAX/Rab8 binding re-
duced numbers of CTLA-4-containing vesicles and its coreceptor surface expression. LAX also promoted the polarization of
CTLA-4 and the reorientation of the microtubule-organizing center to the site of T-cell receptor engagement. Our results iden-
tify a novel CTLA-4/TRIM/LAX/Rab8 effector complex in the transport of CTLA-4 to the surfaces of T cells.
The T-cell coreceptor cytotoxic T-cell antigen 4 (CTLA-4) func-tions as a critical inhibitory regulator of T-cell responses. Its
importance is demonstrated by the autoimmune phenotype of
CTLA-4-deficient mice where polyclonal T-cell proliferation
leads to massive tissue infiltration and early lethality due to organ
destruction (1, 2). In addition, small nucleotide polymorphisms
in the human CTLA-4 gene region have been implicated in nu-
merous autoimmune disorders, including type 1 diabetes (3). Sev-
eral mechanisms have been reported to account for CTLA-4 inhi-
bition, including cell intrinsic and extrinsic pathways. Intrinsic
pathways include inhibition of ZAP-70 microcluster formation
(4), disruption of CD28 localization at the immunological synapse
(5), and alteration of T-cell receptor (TCR) signaling by associated
phosphatases SHP-2 and protein phosphatase 2A (PP2A) (6, 7), as
well as interference with mechanisms such as ectodomain compe-
tition for CD28 binding to CD80 and CD86 (8) or their down-
regulation or removal by CTLA-4 (9) and the release of indoleam-
ine 2,3-dioxygenase (10) and transforming growth factor  (11).
Further, we have shown that CTLA-4 ligation activates the small
GTPase Rap-1, leading to an increase in LFA-1-induced cell adhe-
sion and motility (12, 13). Increased cell motility potently reduces
the TCR-mediated stop signal and contact times with antigen-
presenting cells, resulting in attenuated T-cell activation (12–15).
The induction of motility has been confirmed by several labora-
tories (16–18).
Despite its importance for properly controlled immune re-
sponses, surface expression of CTLA-4 is tightly regulated with the
majority of the coreceptor being localized in intracellular com-
partments such as the trans-Golgi network (TGN), endosomes,
and lysosomes (19–23). The mechanism(s) regulating CTLA-4
surface expression has been unclear. Activated T cells in the lym-
phoproliferative disease Chediak-Higashi syndrome (CHS) lack-
ing CTLA-4 expression have been proposed to play a role in CHS
(24). Trafficking of CTLA-4 from the TGN to the plasma mem-
brane is mediated by binding to the immune cell-specific type I
transmembrane adapter TRIM (T-cell receptor-interacting mol-
ecule) (22, 25). Downregulation of TRIM significantly reduces
CTLA-4 surface expression while retaining the coreceptor in the
TGN (22, 25). In contrast, increased TRIM expression releases
CTLA-4 to the cell surface, resulting in enhanced suppression of
T-cell activation. On the cell surface, phosphorylated CTLA-4
binds to the lipid kinase phosphatidylinositol 3-kinase (PI3K)
(26), while the nonphosphorylated CTLA-4 associates with the
clathrin adapter complex AP-2 (20, 27–30). AP-2 mediates the
internalization of CTLA-4 to intracellular compartments, whereas
AP-1 regulates trafficking of CTLA-4 by shuttling the receptor
from the TGN to lysosomes (20, 31).
Immune cell-specific transmembrane adaptor proteins such as
LAT (linker for activation of T cells), SIT (SHP2 interacting trans-
membrane adapter protein), and LAX (linker for activation of X
cells) are characterized by having a truncated non-ligand-binding
extracellular domain, a transmembrane region, and an extended
cytoplasmic tail (32). The TCR zeta chain is needed for the trans-
port of the antigen receptor (TCR) to the cell surface (33). A sim-
ilar role has been defined with TRIM in its promotion of the sur-
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face expression of CTLA-4 (22). Together, these observations have
begun to implicate transmembrane type I adaptor proteins in the
transport of cargo to the cell surface. TRIM-deficient mice also
display no apparent defect in immune function (34), suggesting
that other transmembrane adaptors may compensate for the ab-
sence of TRIM (34). At the same time, the non-raft-associated
transmembrane adaptor proteins SIT and LAX act as negative
regulators of T-cell activation (35, 36). There has been no evidence
to indicate that either of these adaptors is involved in intracellular
trafficking.
Besides adaptor proteins, small GTPases of the Rho family con-
trol the formation of lamellipodia, filopodia, and focal adhesions
during cell morphogenesis (37). Of these, Rab proteins are mem-
bers of the Ras superfamily that contain a conserved GTP/GDP-
binding site. Furthermore, Rab proteins are described as regula-
tors of protein transport of the secretory and endocytic pathways
(38, 39). Rab5 is reported to control membrane trafficking from
the plasma membrane to early endosomes (40). Many effectors,
such as EEA1 and rabenosyn 5, are involved in this pathway (41–
43). In contrast, Rab8 has been linked to the organization of the
endocytic compartment (44), where it localizes to the endosomal
recycling compartment (45, 46) and colocalizes with EHD1 (EH
domain-containing protein 1) (47) and partially with Rab11 (44).
Rab8 alters the reorganization of actin and microtubules, as well as
directing membrane transport to cell surfaces (48, 49). Depletion
of Rab8 promotes the formation of actin stress fibers, whereas its
activation can lead to cell protrusions (44, 50). Further, Rab8 in-
teracts via optineurin with myosin Vb (51) and has also been
reported to bind mitogen-activated protein kinase kinase kinase
kinase 2 (MAP4K2) (52), the coiled-coil protein FIP-2 (53), and
rab8ip/GC kinase, a participant in tumor necrosis factor alpha-
mediated signaling pathway (52). In addition, the 2B- and 2-
adrenergic receptors have been described to bind Rab8 for trans-
port to the plasma membrane (54). Despite its high expression in
T cells, no immune cell-specific binding effectors of Rab8 have
been identified.
While we previously showed that CTLA-4 binds to the im-
mune adaptor TRIM in T cells, the exact nature of the transport
complex has been unclear. In the present study, we demonstrate
that CTLA-4 forms a multimeric complex comprised of TRIM
and related LAX that binds to GTP bound Rab8 for post-Golgi
transport to the cell surface. Wild-type LAX (LAX WT) or its N
terminus (residues 1 to 77) increased CTLA-4 surface expression,
whereas small interfering RNAs (siRNAs) of Rab8 and LAX re-
duced the numbers of CTLA-4-containing vesicles and its core-
ceptor surface expression. Our results identify a novel CTLA-4/
TRIM/LAX/Rab8 effector complex in the transport of CTLA-4 to
the surfaces of T cells.
MATERIALS AND METHODS
Reagents and plasmids. Anti-myc and alpha-tubulin antibodies were pur-
chased from Millipore, antihemagglutinin (anti-HA) from Covance, anti-SIT
from BioLegend, anti-LAT from Upstate Biotechnology, anti-TRIM from
Abcam, anti-syntaxin-6 and Rab8 from BD Bioscience, anti-CD3 (145-
2C11) from BioXCell (West Lebanon, NH), anti-human CTLA-4 conju-
gated to phycoerythrin (PE) and mouse IgG2a conjugated to PE from BD
Pharmingen, anti-V5 and Alexa-conjugated secondary antibodies from
Invitrogen, and horseradish peroxidase (HRP)-conjugated secondary an-
tibodies from Jackson Immuno-Research. Anti-mouse CTLA-4 was pur-
chased from Santa Cruz. Anti-human CD28 (9.3) was from Bristol Mey-
ers Squibb, and anti-human CTLA-4 (BNI3) and polyclonal anti-LAX
antibodies were kindly provided by B. Bröker (Greifswald, Germany) and
W. Zhang (Durham, NC), respectively.
CTLA-4, CD28, and TRIM plasmids have been described elsewhere
(20, 22). pcDNA3 CTLA-4 tailless was a gift from A. Hueber (Erlangen,
Germany). pCEFL myc-LAX and pEF6 myc-His-LAX were kindly pro-
vided by W. Zhang (Durham, NC) and V. Shapiro (Rochester, NY), re-
spectively. pEGFP myc-Rab8 wild type, pEGFP-Rab8Q67L, pEGFP-
Rab8T22N, and pEGFP-Rab27 were kindly provided by J. Peränen
(Helsinki, Finland). pcDNA3 myc-LAT was a generous gift from L.
Samelson (Bethesda, MD). A plasmid containing full-length SIT cDNA
(Open Biosystems) was amplified by PCR using the primers 5=-CACCAT
GAACCAGGCTGACCC-3= and 3=-TCACAGATCCTCTTCTGAGATG
AGTTTTTGTTCGCTGGCTGCAGGCTG-5=. A C-terminal myc tag was
cloned into the pcDNA3.1 directional TOPO expression vector (Invitro-
gen). LAX1-77 and LAX1-75 mutants were generated by PCR from the
LAX plasmid using the same forward primer but different reverse primers:
LAX forward, 5=-GCGGATCCCCTGATACAATGGATGG-3=; LAX1-77
reverse, 5=-GCTCTAGACATGACGGTAACTCGGAGGTAAG-3=; and
LAX1-75 reverse, 5=-GCTCTAGAGGTAACTCGGAGGTAAGGAACTT
G-3=. PCR products were digested using BamHI and XbaI and cloned into
the pEF6 myc-His plasmid (Invitrogen). LAX- and Rab8-specific siRNAs
(catalog numbers M-064303-00-0005 and M-040860-00-0005, respec-
tively) consisting of four siRNA duplexes for each gene, and control non-
targeting siRNAs (catalog number D-001206-13-05) were purchased
from Dharmacon (Lafayette, CO).
Cells and transfection. DC27.10 cells stably transfected with CTLA-4
(DC27.10 –CTLA-4) were cultured and transfected as described previ-
ously (20, 22). 293T cells, grown in Dulbecco modified Eagle medium
with 10% fetal bovine serum, were transfected using Lipofectamine 2000
(Invitrogen). Murine T cells were transfected with LAX siRNA or Rab8
siRNA and controls (600 nM) using an Amaxa Nucleofector kit (Lonza,
Germany).
IL-2 assay. DC27.10 –CTLA-4 cells were transfected with control
(mock), LAT, LAX, or TRIM and stimulated with plate-bound anti-CD3
(1 g/ml) or anti-CD3/CTLA-4 (1 and 10 g/ml, respectively). After 24 h,
supernatants were taken, and the interleukin-2 (IL-2) concentration de-
termined by enzyme-linked immunosorbent assay (ELISA; BD Biosci-
ences) according to the manufacturer’s protocol.
Transfected primary murine T cells were stimulated with plate-bound
anti-CD3 (2.5 g/ml) or anti-CD3/CTLA-4 (2.5 and 10 g/ml, respec-
tively). After 48 h, intracellular staining for IL-2 was performed as de-
scribed previously (12).
Immunoprecipitation and immunoblotting. Immunoprecipitation
and blotting were performed as previously described (20, 22). Briefly, cells
were lysed in ice-cold lysis buffer (1% Triton X-100, 20 mM Tris, 150 mM
NaCl [pH 8.0]) containing protease and phosphatase inhibitors. Post-
nuclear lysates were incubated for 1 h with the indicated antibody. Protein
A- or G-Sepharose beads (GE Healthcare) were added, followed by incu-
bation for 1 h at 4°C. The eluted proteins were separated by SDS-PAGE
and transferred onto polyvinylidene difluoride membrane for immuno-
blotting. Membranes were blocked with 5% milk in phosphate-buffered
saline (PBS)–1% Tween and incubated with the indicated antibody for 1
h. Bound antibody was revealed with the appropriate secondary antibody
and protein was visualized by enhanced chemiluminescence using ECL
(GE Healthcare).
Immunofluorescence. Cells were harvested, washed in PBS and fixed
in Cytofix (BD Bioscience) for 30 min at 4°C. Cells were then permeabil-
ized in PBS containing 0.5% saponin and 1% bovine serum albumin
(BSA) for 90 min with primary antibody for 1 h. Cells were then washed in
PBS containing 0.1% saponin and 1% BSA and incubated with fluores-
cently labeled secondary antibody for 1 h. Incubation and washing for
subsequent primary and secondary antibodies was repeated for double-
and triple-stained cells. After the final wash, cells were resuspended in
Vectashield mounting medium containing DAPI (4=,6=-diamidino-2-
phenylindole; Vector Laboratories), mounted onto microscope slides,
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and sealed with nail varnish. Image acquisition was performed with a Zeiss
LSM510 confocal microscope using an 63 PlanApochromat/1.4-
numerical-aperture oil objective lens. Lasers of 405 (DAPI)-, 488 (Alexa
Fluor 488)-, 543 (Alexa Fluor 568)-, and 633 (Alexa Fluor 647)-nm wave-
lengths were used for fluorescence excitation. Images were analyzed using
Fiji.
MTOC reorientation assay. Transfected DC27.10 –CTLA-4 cells were
seeded onto poly-D-lysine (Sigma-Aldrich)-coated coverslips in six-well
plates. After binding, anti-CD3 (145-2C11)- or isotype-coated Dynabeads
(4.5 m in diameter [Invitrogen], prepared according to the manufactur-
er’s instructions) were mixed with the cells at a 1:1 ratio, followed by
incubation at 37°C for 15, 30, and 60 min. Cells were then washed and
fixed in 4% paraformaldehyde for 10 min, washed thrice in PBS, perme-
abilized with 0.1% Triton X-100 for 10 min, washed twice in PBS, and
blocked with 3% BSA in PBS for 1 h. Cells were then incubated with the
respective antibodies. Washing and antibody incubation was repeated for
subsequent antibodies in double- and triple-stained cells. After the final
wash, cells on coverslips were mounted onto microscope slides with
Vectashield mounting medium containing DAPI (Vector Laboratories).
Microtubule-organizing center (MTOC) reorientation was determined
by observing the samples with a Zeiss Axiophot fluorescence microscope
and counting the number of cells whose MTOC position (as determined
by tubulin staining) was juxtaposed to a bead in contact with the cell.
Polarized MTOC was defined by being within 3 m from the cell-bead
contact area.
RESULTS
Rab8 colocalizes with and binds to the immune specific adaptor
LAX. We previously found that immune cell adaptor TRIM asso-
ciates with CTLA-4 and is needed for its transport to the surfaces
of T cells (22). The small GTPase Rab8 has been reported to be
involved in the trafficking of newly synthesized proteins from the
TGN to the plasma membrane (55). However, a possible role of
Rab8 and associated immune cell-specific adaptors in this process
has been unclear. To assess the role of Rab8 on CTLA-4 expres-
sion, we first investigated colocalization of CTLA-4 with Rab8 and
immune cell adaptors TRIM or LAX (Fig. 1A). For this, preacti-
vated primary T cells were stained for endogenous protein using
anti-CTLA-4, anti-LAX or anti-TRIM in combination with an
Alexa Fluor 568-coupled secondary antibody, followed by anti-
Rab8 plus Alexa Fluor 488. As we previously reported, CTLA-4
and TRIM stained the TGN and surrounding vesicles (Fig. 1Aa
and b) (22). Intriguingly, anti-LAX stained the same region (Fig.
1Ac) that colocalized with the syntaxin-6 staining of the TGN (Fig.
1Ad). Anti-Rab8 also stained the TGN and surrounding vesicles,
whereas a subset of Rab8 vesicles stained positive for CTLA-4
(upper panel, see arrows and merged single slice figure). A similar
pattern of colocalization was observed between Rab8 and TRIM
(middle panel) and LAX (lower panel). These data suggested a
potential interaction between CTLA-4, TRIM, and/or LAX and
Rab8 in the TGN and proximal vesicles.
Given this colocalization, we sought to determine whether
Rab8 could bind CTLA-4, TRIM, and/or LAX (Fig. 1B). Thus far,
no immune cell-specific adaptors have been reported to associate
with Rab8. Jurkat T cells were therefore lysed and subjected to
precipitation with anti-TRIM or anti-LAX, followed by immuno-
blotting with anti-Rab8. Although anti-LAX coprecipitated Rab8
(Fig. 1B, lane 3), anti-TRIM precipitated only little Rab8 (Fig. 1B,
lanes 2). As a control, cell lysates blotted with anti-Rab8 showed
equal sample loading (Fig. 1B, lower panel, lanes 1 to 3).
To confirm this observation by cotransfection in nonlymphoid
cells, mock, CTLA-4, HA-TRIM, or myc-LAX were coexpressed
with pEGFP-myc-Rab8 in 293T cells, followed by precipitation
with anti-CTLA-4, anti-HA, or anti-LAX and blotting with anti-
Rab8 (Fig. 1C, lanes 1 to 6). Although CTLA-4 and TRIM failed to
bind to Rab8 (Fig. 1C, lanes 2 and 4), anti-LAX readily precipi-
tated Rab8 from cells cotransfected with myc-LAX and pEFGP-
myc-Rab8 (Fig. 1C, lane 6). As a further control, neither anti-
CTLA-4, TRIM, nor LAX coprecipitated Rab27 from cells
cotransfected with pEGFP-Rab27 (Fig. 1D). These data indicated
that LAX, but neither CTLA-4 nor TRIM, bound to Rab8.
Next, it was important to assess whether LAX bound preferen-
tially to the active GTP-bound form of Rab8 (Fig. 2A). LAX was
therefore coexpressed in 293T cells with active (Q67L) and inac-
tive (T22N) Rab8, followed by precipitation with anti-LAX and
immunoblotting for Rab8. Strikingly, LAX associated with sub-
stantially more Q67LRab8 compared to inactive TN22Rab8 (Fig.
2A, upper panel, lane 3 versus lane 4). The faster migration of
Q67LRab8 and TN22Rab8 compared to wild-type Rab8 is due to
the absence of the myc-tag. An overexposed version of lane 4 (*)
also revealed a lower fainter band present in the pulldowns of
wild-type Rab8 and Q67LRab8, most likely representing a degra-
dation product. Cell lysates blotted with anti-Rab8 revealed equal
sample loading (Fig. 2A, lower panel, lanes 1 to 4). These data
indicated that the active form of Rab8 binds with higher affinity to
LAX than the inactive form.
Given this finding, we assessed whether Rab8 was needed for
optimal CTLA-4 surface expression (sCTLA-4) (Fig. 2B). Primary
T cells were transfected with Rab8 siRNA, followed by anti-CD3/
CD28 coligation and analysis of sCTLA-4 72 h after transfection.
Immunoblotting of cell lysates showed reduced Rab8 expression
in Rab8 siRNA-transfected cells (Fig. 2B, upper panel). Concur-
rent with this was a substantial reduction in the mean fluorescence
intensity (MFI) of sCTLA-4 compared to cells transfected with
control siRNA (107 versus 182) as detected by flow cytometry
(Fig. 2B, lower panel). These data indicated that CTLA-4 required
Rab8 for optimal transport to the cell surface.
In an attempt to map the site of binding, mutants of LAX
consisting of the N-terminal amino acids 1 to 75 or 1 to 77 were
generated (Fig. 2C) and assessed for binding to Rab8. For this,
293T cells cotransfected with pEGFP-myc-Rab8 and mock, myc-
LAX1-77, or myc-LAX1-75 were precipitated with anti-LAX and
blotted for Rab8 (Fig. 2C, lower panel, lanes 1 to 3). LAX1-77
readily precipitated Rab8 (Fig. 2C, lower panel, lane 2), while
LAX1-75 failed to associate with Rab8 (lane 3). Cell lysates blotted
with anti-Rab8 showed equal sample loading (Fig. 2C, lower
panel, lanes 1 to 3). Lax mutant 1-75 was slightly less expressed
compared to mutant 1-77 (Fig. 2C, middle panel, lane 3 versus
lane 2). Further, overexpression of LAX1-75 into DC27.10 cells
stably transfected with CTLA-4 (DC27.10 –CTLA-4) (20, 22)
failed to support the increase in CTLA-4 surface expression ob-
served with LAX WT (Fig. 2D). Although LAX WT increased the
expression of CTLA-4 from 64.46 to 81.08%, LAX 1-75 showed a
decrease from 64.46 to 53.8%. Together, these data indicated that
the N-terminal region bound to Rab8, and this interaction played
a role in the transport of CTLA-4 to the cell surface.
Binding of LAX to TRIM in T cells. The binding of active Rab8
to LAX raised the question regarding the nature of the effector
complex in T cells. We therefore further investigated the interac-
tion of LAX with TRIM and CTLA-4 by initially using three-color
immunofluorescence (Fig. 3A). Preactivated primary T cells were
stained with biotinylated anti-CTLA-4 plus streptavidin-Alexa
Banton et al.
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FIG 1 Rab8 colocalizes with CTLA-4, LAX, and TRIM. (A) Preactivated human T cells were stained with anti-CTLA-4 plus Alexa Fluor 568, followed by
anti-Rab8 plus Alexa Fluor 488 (a), anti-TRIM plus Alexa Fluor 568 (b), or with anti-LAX plus Alexa Fluor 568 (c) and analyzed for colocalization (yellow,
merged images) by confocal microscopy. Bar, 10 m. The enlarged image shows a representative cell for colocalization with Rab8 and CTLA-4 (top), TRIM
(middle), and LAX (bottom). Bar, 2.5 m. (d) DC27.10 –CTLA-4 cells were stained with anti-LAX, followed by anti-rabbit antibody–Alexa Fluor 568. In
addition, cells were stained with anti-syntaxin-6, a marker for the Golgi apparatus, and assessed by confocal microscopy (TGN, green; LAX, red). Bar, 10 m. (B)
LAX binds to Rab8. Jurkat cells were immunoprecipitated with control antibody (IgG, lane 1), anti-TRIM (lane 2), or anti-LAX (lane 3) and blotted with
anti-Rab8 MAb. Anti-Rab8 blotting of cell lysates served as a loading control (bottom panel). (C) LAX, but not TRIM, specifically binds to Rab8 and not to Rab27.
293T cells cotransfected with as indicated were immunoprecipitated with anti-CTLA-4 (lanes 1 and 2), anti-HA (lanes 3 and 4), or anti-LAX (lanes 5 and 6).
Immunoblots were probed with anti-Rab8 (top panel), anti-myc (second panel), anti-HA (middle panel), or anti-CTLA-4 (fourth panel). Anti-Rab8 blotting of
cell lysates served as a loading control (bottom panel). (D) 293T cells cotransfected as indicated were immunoprecipitated with anti-CTLA-4 (lanes 1 and 2),
anti-HA (lanes 3 and 4), or anti-LAX (lanes 5 and 6). Immunoblots were probed with anti-Rab27 (top panel), anti-myc (second panel), anti-HA (middle panel),
or anti-CTLA-4 (fourth panel). Anti-Rab27 blotting of cell lysates served as a loading control (bottom panel).
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568 (upper left panel), anti-LAX plus anti-rabbit antibody–Alexa
488 (upper middle panel) or anti-TRIM plus anti-mouse anti-
body–Alexa 647 (upper right panel) and analyzed by confocal mi-
croscopy. CTLA-4, LAX, and TRIM colocalized in the TGN and
surrounding vesicles as viewed within a single confocal slice
(lower panel). The only difference was the occasional staining of
LAX in vesicles in other regions of the cells.
To test whether LAX could bind to CTLA-4, V5-tagged
CTLA-4 was coexpressed with myc-tagged LAT, LAX, or SIT in
293T cells, followed by precipitation with anti-CTLA-4 and blot-
ting with anti-myc antibody (Fig. 3B). Anti-CTLA-4 coprecipi-
tated LAX (Fig. 3B, left panel, lane 7) but neither LAT (lane 6) nor
SIT (lane 8). The adaptors were expressed at similar levels as de-
tected by blotting of cell lysates (Fig. 3B, lanes 2 to 4). Further,
unlike CTLA-4, CD28 failed to associate with LAX (Fig. 3B, right
panel, lane 7). In addition to cells transfected with LAX, CTLA-4
also associated with endogenous LAX in preactivated primary T
cells (49% of these activated T cells expressed CTLA-4) (Fig. 3C,
left histogram) as detected by anti-LAX blotting (right panel, lane
2). Cell lysates blotted with antiactin served as a loading control
(lower panel). Further, as an additional control, a comparison of
cells transfected with CTLA-4 and HA-TRIM or myc-LAX
FIG 2 (A) Binding of LAX to wild-type and constitutively active Rab8. 293T cells cotransfected as indicated were immunoprecipitated with anti-LAX and blotted
for Rab8 (upper panel). Anti-Rab8 blotting of cell lysates served as a loading control. The faster migration of Q67LRab8 and TN22Rab8 compared to wild-type
Rab8 is due to the absence of the myc tag. *, overexposed version of lane 4. (B) Rab8 siRNA reduces CTLA-4 surface expression. Murine T cells were transfected
with control or Rab8 siRNA and stimulated with ConA (2.5 g/ml). After 3 days, cells were washed and stained for CTLA-4 with anti-CTLA-4 –PE. A histogram
shows the MFI of CTLA-4-positive cells. The inset shows reduced Rab8 expression in cells transfected with Rab8 siRNA, as demonstrated by blotting with
anti-Rab8. (C) Rab8 binds to the N terminus of LAX. The upper panel shows a depiction of N-terminal LAX constructs. For the lower panel, 293T cells
cotransfected as indicated were immunoprecipitated with anti-LAX and blotted for Rab8 (top panel). Cell lysates were blotted for LAX (middle panel) and Rab8
(bottom panel). (D) Reduced CTLA-4 surface expression in LAX1-75-transfected cells. Mock-, wild-type LAX-, LAX 1-77-, and LAX1-75-transfected DC27.10 –
CTLA-4 cells were stained with CTLA-4 –PE and analyzed by fluorescence-activated cell sorting (FACS).
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showed that anti-CTLA-4 precipitated both TRIM (Fig. 4A, upper
left panel, lane 2) and LAX (upper middle panel, lane 4). The
interaction between LAX and CTLA-4 could also be demonstrated
by immunoprecipitating LAX and blotting for CTLA-4 (Fig. 4A,
upper right panel, lane 6). It was next of interest to assess whether
binding of LAX to CTLA-4 requires its cytoplasmic tail or its in-
teraction with PI3K or the clathrin adaptor AP-2. Several point
mutations of CTLA-4 and tailless (TL) CTLA-4 (Fig. 4A, middle
panel) were coexpressed with LAX in 293T cells, followed by pre-
cipitation with anti-CTLA-4 and blotting with anti-LAX antibody
(lower left panel). Neither mutations of the two tyrosine-based
motifs of CTLA-4 nor mutations of its proline- and lysine-rich
motifs prevented the interaction between LAX and CTLA-4 (Fig.
4A, middle panel, lanes 3 to 7 versus lane 2). Although the cyto-
plasmic domain of CTLA-4 is needed for binding to LAX (lane 8),
it is independent of its interaction with PI3K (Fig. 4A, middle
panel, lanes 3 and 5) and AP-2 (lane 3). Middle and lower panels
show equal expression of the various CTLA-4 mutants and wild-
FIG 3 (A, top) Colocalization of CTLA-4, LAX, and TRIM in primary human T cells. Preactivated human T cells were stained with biotinylated anti-CTLA-4
plus streptavidin-Alexa Fluor 568 (CTLA-4 panel), anti-LAX plus anti-rabbit antibody–Alexa Fluor 488 (LAX panel), and anti-TRIM plus anti-mouse antibody–
Alexa Fluor 647 (TRIM panel) and analyzed by confocal microscopy. (Bottom) Colocalization of CTLA-4/LAX (magenta), CTLA-4/TRIM (yellow), TRIM/LAX
(cyan), and CTLA-4/TRIM/LAX (white) occurred mainly in the TGN area. Bars, 2.5 m. (B) CTLA-4 binds to LAX but not LAT or SIT. In the left panel, 293T
cells V5-CLTA-4 cotransfected as indicated were immunoprecipitated with anti-CTLA-4. Immunoblots were probed with anti-myc and anti-V5. For the
detection of LAX, HRP–mouse anti-rabbit light chain, which did not react with the heavy chain of the precipitating CTLA-4 antibody, was used. In the right panel,
293T cells cotransfected as indicated were immunoprecipitated with anti-CD28. Immunoblots were probed with anti-myc and anti-CD28. For the detection of
LAX, HRP–mouse anti-rabbit light chain, which did not react with the heavy chain of the precipitating CD28 antibody, was used. (C) For the left panel, activated
murine T cells were stained with anti-CTLA-4-APC and analyzed by FACS for CTLA-4. For the right panel, activated murine T cells were lysed, immunopre-
cipitated with anti-CD28, anti-CTLA-4, and anti-LAX, and immunoblotted with anti-LAX. For the lower panel, cell lysates blotted with antiactin served as a
loading control.
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FIG 4 (A) Binding of LAX to CTLA-4 requires its cytoplasmic tail but is independent of its PI3K and AP-2 interaction. For the upper left panel, 293T cells that
were mock and HA-TRIM cotransfected (lane 1) or CTLA-4 and HA-TRIM cotransfected (lane 2) were immunoprecipitated with anti-CTLA-4 and blotted with
anti-HA. Anti-CTLA-4 (middle panel) or anti-HA (bottom panel) blotting of cell lysates served as a loading control. For the upper middle panel, 293T cells that
were mock and CTLA-4 cotransfected (lane 3) or CTLA-4 and myc-LAX cotransfected (lane 4) were immunoprecipitated with anti-CTLA-4 and blotted with
anti-myc. Anti-myc (middle panel) or anti-CTLA-4 (bottom panel) blotting of cell lysates served as a loading control. For the upper right panel, 293T cells that
were mock and myc-LAX cotransfected (lane 5) or CTLA-4 and myc-LAX cotransfected (lane 6) were immunoprecipitated with anti-LAX and blotted with
anti-CTLA-4. Anti-CTLA-4 (middle panel) or anti-myc (bottom panel) blotting of cell lysates served as a loading control. The middle panel shows wild-type
CTLA-4, tailless CTLA-4, and point mutations of the tyrosine-, lysine-, and proline-rich motifs. For the lower left panel, 293T cells cotransfected as indicated
(mut., mutant; TL, tailless) were immunoprecipitated with anti-CTLA-4 and blotted with anti-LAX (top panel). Blotting of cell lysates with V5 or LAX antibodies
show equal expression of the various CTLA-4 mutants (middle panel) and wild-type LAX (bottom panel). The lower right panel shows the binding of LAX1-77
to CTLA-4. 293T cells cotransfected as indicated were precipitated with anti-CTLA-4 and blotted with anti-LAX (lanes 1 to 3). Cell lysates blotted with anti-LAX
(upper panel) or anti-CTLA-4 (lower panel) served as a loading control (lanes 4 to 6). (B) The upper left panel shows that the overexpression of TRIM does not
interfere in the binding of LAX to CTLA-4. Mock/TRIM (lane 1), Mock/LAX (lane 2), CTLA-4/LAX (lane 3), CTLA-4/TRIM (lane 4), or CTLA-4/TRIM/LAX
(lane 5) were coexpressed in 293T cells, precipitated with anti-CTLA-4, and blotted for LAX (top panel) and TRIM (bottom panel). The third, fourth, and bottom
panels show equal expression of TRIM, LAX, and CTLA-4 as revealed by blotting of cell lysates with anti-HA, anti-LAX, and anti-CTLA-4 antibodies, respec-
tively. The upper right panel shows the binding of LAX to TRIM. 293T cells that were mock and HA-TRIM transfected (lane1) or myc-LAX and HA-TRIM
transfected (lane 2) were immunoprecipitated with anti-LAX and blotted with anti-HA. Anti-myc (middle panel) or anti-HA (bottom panel) blotting of cell
lysates served as a loading control. For the lower left panel, 293T cells that were V5-Rab8 and mock cotransfected (lane 1) or CTLA-4, HA-TRIM, and myc-LAX
cotransfected (lane 2) were immunoprecipitated with anti-CTLA-4 and blotted with anti-Rab8 (top panel), anti-CTLA-4 (second panel), anti-LAX (third panel),
and anti-HA (fourth panel). Anti-Rab8 blotting of cell lysates served as a loading control (bottom panel). For the detection of LAX, HRP–mouse anti-rabbit light
chain, which did not react with the heavy chain of the precipitating CTLA-4 antibody, was used. For the detection of Rab8 and TRIM, HRP– goat anti-mouse Fc
fragment specific IgG, which did not react with the light chain of the precipitating CTLA-4 antibody, was used. For the lower right panel, 293T cells V5-Rab8 and
mock cotransfected (lane 1) or CTLA-4 and HA-TRIM cotransfected (lane 2) were immunoprecipitated with anti-CTLA-4 and blotted with anti-Rab8 (top
panel), anti-HA (third panel), and anti-CTLA-4 (bottom panel). Anti-Rab8 blotting of cell lysates served as a loading control (second panel). For the detection
of Rab8 and TRIM, HRP– goat anti-mouse Fc fragment-specific IgG, which did not react with the light chain of the precipitating CTLA-4 antibody, was used.
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type LAX, respectively. To assess whether the Rab8 binding
LAX1-77 was sufficient to associate with CTLA-4, wild-type LAX
and LAX1-77 were coexpressed with CTlA-4 in 293T cells, immu-
noprecipitated with anti-CTLA-4 and blotted with anti-LAX an-
tibody. Like wild-type LAX, mutant LAX1-77 could precipitate
CTLA-4 (Fig. 4A, lower right panel, lane 3 versus lane 2).
It was next of interest to assess whether overexpression of
TRIM would interfere in the binding of LAX to CTLA-4. To test
this, CTLA-4, TRIM and LAX were coexpressed in 293T cells,
precipitated with anti-CTLA-4 and blotted for LAX and TRIM
(Fig. 4B, upper left panel). The amount of CTLA-4-associated
LAX was comparable to that precipitated with anti-CTLA-4 from
cells transfected with CTLA-4 and LAX in the absence of TRIM
(Fig. 4B, upper left panel, lane 5 versus lane 3); the middle, upper,
and lower panels in this portion of Fig. 4B show equal expression
of TRIM, LAX, and CTLA-4, respectively. This finding indicates
that LAX and TRIM in the complex are complementary and not
competitive.
Notably, anti-LAX also coprecipitated TRIM from cells trans-
fected with HA-TRIM and myc-LAX (Fig. 4B, upper right panel,
lane 2 versus lane 1). These data indicated that in addition to the
association of LAX with Rab8, LAX also bound to CTLA-4 and
TRIM. To prove this further, CTLA-4 was cotransfected with
LAX, TRIM, and Rab8 into 293T cells, precipitated with anti-
CTLA-4, and blotted for Rab8 (Fig. 4B, lower left panel, lane 2).
Under this condition, anti-CTLA-4 could precipitate Rab8, sug-
gesting that the LAX/Rab8 complex is important for CTLA-4
transport to the surface of T cells. As a control, cotransfection of
CTLA-4, TRIM, and Rab8, followed by immunoprecipitation
with anti-CTLA-4 and blotting for Rab8, failed to show the inter-
action between CTLA-4 and Rab8 (Fig. 4B, lower right panel, lane
2) but did show binding to TRIM (upper lower panel, lane 2).
LAX modulates CTLA-4 surface expression and IL-2 produc-
tion. Given the connection between Rab8 and LAX, as well as
between CTLA-4 and LAX, it was of interest to assess whether LAX
could modulate CTLA-4 surface expression. DC27.10 –CTLA-4
cells that were mock, LAT, TRIM, or LAX transfected were ini-
tially stained and analyzed for surface CTLA-4 using anti-CTLA-
4 –PE in the absence of anti-CD3 ligation (Fig. 5A). LAX expres-
sion had a marked effect by increasing the MFI of sCTLA-4 from
24 to 64; TRIM increased the MFI for sCTLA-4 from 24 to 50.
Importantly, as a negative control, expression of LAT had no effect
on the MFI or the percent expression of sCTLA-4. Further, trans-
fection of TRIM or LAX did not alter CD3 or CD28 surface ex-
pression (Fig. 5A, middle and right panels). The levels of trans-
fected LAX, LAT, and TRIM are shown, as determined by
immunoblotting (upper inset). These observations indicated that
LAX had the ability to selectively increase CTLA-4 surface expres-
sion in the absence of anti-CD3 ligation. LAX modulation of
sCTLA-4 occurred independently of its reported effect on TCR
signaling (36).
Further, LAX cooperated with anti-CD3 ligation to increase
sCTLA-4 (Fig. 5B). The ability of anti-CD3 stimulation to induce
CTLA-4 expression has been well documented (23). Mock- or
LAX-transfected DC27.10 –CTLA-4 cells were either left un-
treated (Fig. 5B, left panel) or stimulated with plate-bound anti-
CD3 (1 g/ml) (Fig. 5B, middle panel). After 36 h, the cells were
stained and analyzed for sCTLA-4 expression. LAX increased the
MFI for sCTLA-4 from 28 to 71, whereas anti-CD3 alone in-
creased the MFI from 28 to 45 (right histogram). The combina-
tion of anti-CD3 and LAX cooperated to increase the MFI for
sCTLA-4 to 77. These data indicated that LAX and anti-CD3 ef-
fectively cooperate to induce high levels of surface CTLA-4 on T
cells.
Importantly, this increase in expression of surface CTLA-4 in-
duced by LAX resulted in a profound increase on the level of
inhibition of IL-2 production when expressed with coligation by
anti-CD3 and anti-CTLA-4 (Fig. 5C, left panel). Although anti-
CTLA-4 inhibited IL-2 production by 45 to 50% in mock- or
LAT-transfected cells, cells expressing LAX or TRIM showed in-
hibition of IL-2 production by 80 to 90%. In contrast, as a control,
LAX and TRIM expression inhibited anti-CD3-induced IL-2 pro-
duction by 32 and 43%, respectively (middle panel). This is in
accordance with a previous report demonstrating that LAX can
inhibit TCR signaling (36), although the effect with anti-CD3
alone was considerably lower compared to the coligation of
CTLA-4 (i.e., 32% versus 89%). The increased inhibitory effect on
IL-2 production mediated by anti-CD3/CTLA-4 coligation could
also be demonstrated in primary T cells transfected with LAX and
TRIM (Fig. 5D). Notably, cells transfected with LAX1-77 led to an
inhibition in IL-2 production comparable to that mediated by
LAX WT and TRIM.
Our data therefore show that while LAX can exert a partial
inhibitory effect on TCR signaling, it cannot account for the more
robust inhibition seen with the increased level of CTLA-4 expres-
FIG 4 continued
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sion and inhibition on T cells. These findings demonstrate that
LAX can exert an inhibitory effect on T-cell activation by regulat-
ing the expression of CTLA-4 on the surface of T cells.
Conversely, a reduction in LAX or TRIM expression by shRNA
reduced the presence of CTLA-4 vesicles and cell surface expres-
sion of the coreceptor (Fig. 6). DC27.10 –CTLA-4 cells were trans-
fected with LAX shRNA, stained for intracellular CTLA-4, and
analyzed by confocal microscopy (Fig. 6A). A vesicle within 2.5
m of the TGN was defined as TGN-proximal vesicle. Clearly,
LAX shRNA reduced the number of CTLA-4-containing vesicles
per cell, with the majority being localized in the TGN. Further, trans-
fection of primary T cells with LAX siRNA showed a 4-fold reduction
of the MFI for CTLA-4 surface expression (Fig. 6B). Reduced expres-
sion of LAX in LAX siRNA-transfected cells was detected by blotting
of cell lysates (Fig. 6A, upper inset). Overall, these data indicated that
TRIM and LAX regulate the formation of TGN-proximal CTLA-4-
containing vesicles needed for optimal CTLA-4 surface expression
and increased inhibition of T-cell responses.
LAX modulates CTLA-4 and MTOC polarization. Previous
studies have shown that anti-CD3 ligation induces the polariza-
FIG 5 LAX upregulates CTLA-4 surface expression. (A) Mock-, LAT-, TRIM-, or LAX-transfected DC27.10 –CTLA-4 cells were stained with CTLA-4 –PE,
CD3-PE, and CD28-PE, and the surface expression of CTLA-4, CD3, and CD28 was analyzed by FACS. The inset shows the expression levels of transfected LAX,
LAT, and TRIM. (B) Mock- or LAX-transfected DC27.10 –CTLA-4 cells were either left untreated (left panel) or stimulated with anti-CD3 (1 g/ml, middle
panel). At 36 h after stimulation, cells were stained with anti-CTLA-4 –PE, and the surface expression of CTLA-4 was analyzed by FACS. In the right panel, a
histogram shows the MFIs for surface CTLA-4 in resting and stimulated mock- and LAX-transfected cells. (C) LAX upregulates CTLA-4 function. In the left
panel, Mock-, LAT-, LAX-, or TRIM-transfected DC27.10 –CTLA-4 cells were stimulated with plate-bound anti-CD3 (1 g/ml) or anti-CD3/CTLA-4 (1 g/
ml/10 g/ml.) In the right panel, mock-, LAX-, or TRIM-transfected DC27.10 –CTLA-4 cells were stimulated with plate-bound anti-CD3 (1 g/ml). After 24 h,
the supernatant was taken and analyzed for IL-2 by ELISA. The bar graph shows means  the standard deviations (SD; n  2). (D) Primary murine T cells
transfected with mock, LAXWT, LAX1-77, or TRIM were stimulated with plate-bound anti-CD3 (2.5 g/ml) or anti-CD3/CTLA-4 (2.5 and 10 g/ml,
respectively) and, 48 h later, intracellular staining for IL-2 was performed. The bar graph shows the means  the SD (n  2).
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tion of CTLA-4 to the contact region of T cells (23, 56). To assess
whether LAX could also affect the polarized release of CTLA-4 in
response to anti-CD3 ligation, mock- or LAX-transfected
DC27.10 –CTLA-4 cells were stimulated for various periods of
time with anti-CD3- or isotype-coated Dynabeads. Cells were
then fixed, permeabilized, stained with anti-CTLA-4, and ana-
lyzed by confocal microscopy (Fig. 7A). CTLA-4 polarized vesicles
were defined by being within 4 m from the cell-bead contact
area. Compared to mock-transfected cells, LAX expression accel-
erated and increased the polarization of CTLA-4 to the contact
region between T cells and anti-CD3-coated beads (lower histo-
gram). This was evident as early as 15 to 30 min. By 60 min, the
polarization of CTLA-4 in mock-transfected cells induced by anti-
CD3 alone occurred at levels similar to those seen with the LAX-
transfected cells.
The polarized release of CTLA-4 to the anti-CD3 interface in
turn has previously been correlated with a repositioning of the
MTOC in T cells (56). The increase in polarized CTLA-4 could
therefore be related to an increase in the polarization of the
MTOC. DC27.10 –CTLA-4 cells were therefore mock, LAX, or
TRIM transfected, stimulated with anti-CD3, and then fixed, per-
meabilized, and stained with anti-alpha-tubulin. In activated cells,
the MTOC was clearly oriented toward attached anti-CD3-coated
beads, as revealed by confocal microscopy (Fig. 8, upper panel).
Polarized MTOC was defined by being within 3 m from the
cell-bead contact area. Notably, 70% of cells transfected with LAX
or TRIM had the MTOC reoriented to the interface with beads at
15 min anti-CD3 stimulation compared to only 50% of mock-
transfected cells. This difference could also be observed at 30 min
stimulation. Only after 60 min of stimulation mock-transfected
cells reached the percentage of cells with reoriented MTOC ob-
served in LAX- or TRIM-transfected cells (Fig. 8, lower histo-
gram). Together, our data demonstrated that LAX and TRIM reg-
ulate the MTOC reorientation and the polarization of CTLA-4 to
the contact site of TCR engagement for increased CTLA-4 surface
expression. This is in accordance with the well-established role of
Rab8 in modulating polarized membrane transport to cell sur-
faces (48, 49).
DISCUSSION
Although CTLA-4 is located mostly in the intracellular trans-
Golgi network, the mechanism by which it is transported to the
cell surface had been unclear. In the present study, we have iden-
tified a novel complex comprised of TRIM and related LAX that in
turn binds to GTP bound Rab8 for post-Golgi transport to the cell
surface. LAX bound via its N terminus to active GTP-Rab8, as well
FIG 6 Reduction of TGN-proximal CTLA-4-containing vesicles in cells transfected with shRNAs. (A) For the upper panel, DC27.10 –CTLA-4 cells were
transfected with control shRNA, LAX shRNA, and TRIM shRNA and stained with anti-CTLA-4 –Texas Red 3 days after transfection (left panel). The presence
of CTLA-4-containing vesicles were analyzed by confocal microscopy and ImageJ. Bars, 10 m; bars in the enlarged images, 5 m. The circled area in the enlarged
images indicates the area (2.5 m) in which TGN-proximal vesicles were counted. In the right panel, a histogram shows the numbers of CTLA-4 vesicles from
cells transfected with control, LAX, and TRIM shRNA (n  30 cells for each condition). (B) LAX siRNA reduces CTLA-4 surface expression. Murine T cells were
transfected with control or LAX siRNA and stimulated with concanavalin A (2.5 g/ml). After 3 days, the cells were washed, stained for CTLA-4 with
anti-CTLA-4 –PE, and analyzed by FACS. A histogram shows the MFIs of CTLA-4-positive cells. For the inset, reduced LAX expression in cells transfected with
LAX siRNA is demonstrated by blotting with anti-LAX.
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as the cytoplasmic tail of CTLA-4. TRIM required LAX for bind-
ing to Rab8 in a complex. Wild-type LAX or its N terminus (res-
idues 1 to 77) increased CTLA-4 surface expression, whereas
siRNAs of Rab8 or LAX or disruption of LAX/Rab8 binding re-
duced the numbers of CTLA-4-containing vesicles and its core-
ceptor surface expression. Our findings identify a novel effector of
Rab8 for the transport of CTLA-4 from the trans-Golgi network to
the surfaces of T cells for the mediation of immune suppression.
Rab8 has previously been shown to mediate the trafficking of
newly synthesized proteins from the TGN to the plasma mem-
brane (55). GTP-bound Rab8 has been reported to bind to op-
tineurin (57), MAP4K2 (52), FIP-2 (53), and rab8ip/GC kinase
(52). However, despite high levels of expression in T cells, no
binding partners or effectors of Rab8 have been described. We
have identified here a GTP-Rab8-LAX complex that implicates
LAX as an effector of Rab8 in the regulation of CTLA-4 surface
expression. LAX bound to GTP-Rab8 via its N terminus and the
disruption of LAX/Rab8 binding profoundly reduced the forma-
tion of CTLA-4-containing vesicles and the expression of CTLA-4
on the surfaces of T cells. LAX was bound to CTLA-4, acting as a
bridge between Rab8 and the coreceptor for its transport. As a
control, LAX associated with CTLA-4 but not with the related
CD28. Conversely, CTLA-4 bound to LAX but not to the other
type 1 protein, LAT, that mediates TCR signaling. The shRNA
knockdown of LAX markedly reduced the numbers of CTLA-4-
containing vesicles proximal to the TGN and CTLA-4 surface ex-
pression. In contrast, LAX overexpression increased CTLA-4 sur-
face expression, without affecting the expression of the TCR or
CD28. The LAX-induced increase in CTLA-4 expression led to an
inhibition of T-cell activation upon coligation of CTLA-4 with the
TCR. This finding is in accordance with a reported role of the
adaptor in the inhibition of T-cell activation (36). Overall, LAX is
a novel effector of the Rab8 pathway that controls the transport
and surface expression of CTLA-4 for the inhibition of T-cell re-
sponses.
Previous studies have underscored the importance of Rab8 to
the organization of the endocytic compartment (44) and the re-
modeling of actin and microtubules for directed membrane trans-
port to cell surfaces (48, 49). Despite its high expression in T cells
and the fact that it can interact with effectors in other cell types, no
immune cell-specific binding effectors of Rab8 have been identi-
fied. Our findings therefore identify for the first time LAX as an
immune cell-specific adaptor protein that bound preferentially to
the active GTP-bound form of Rab8 and, as such, is likely to serve
as an effector of Rab8 in T cells. Our findings suggest that LAX
functions as a central coordinator by bridging Rab8 with the other
LAX-associated proteins, TRIM and CTLA-4. Increased LAX ex-
pression in turn increased CTLA-4-containing TGN-proximal
vesicles, cell surface expression, and inhibition of TCR-induced
IL-2 production. At the same time, siRNA knockdown of Rab8 or
a LAX mutant defective in binding to Rab8 impaired the expres-
sion of CTLA-4 at the cell surface. Collectively, these findings
point to a central role for Rab8 and is effector protein, LAX, in the
regulation of the transport of CTLA-4 to the surfaces of T cells for
inhibition of the immune response. These data are of potential
importance to the field of antitumor immunology given the suc-
cessful application of anti-CTLA-4 (Ipilimumab) in the treatment
of late-stage melanoma (58).
FIG 7 LAX increases the polarized release of CTLA-4. DC27.10 –CTLA-4 cells
were mock or LAX transfected and stimulated with anti-CD3-coated beads for
the indicated periods of time. The cells were then fixed, permeabilized, stained
with anti-CTLA-4 –Alexa Fluor 568, and analyzed by confocal microscopy.
Cells with polarized CTLA-4 vesicles in a cell-bead contact area of 4 m were
counted. The upper panel shows an image with polarized CTLA-4 toward the
contact region between T cells and the anti-CD3-coated beads. Bar, 10 m.
The histogram below shows the percentages of cells with polarized CTLA-4
(n  3; 120 to 150 cells/experiment). The means  the SD are displayed.
Differences between means were tested by using two-tailed unpaired Student t
test (*, P 	 0.05 [considered significant]; ns, not significant).
FIG 8 TRIM and LAX accelerate the MTOC reorientation. DC27.10 –CTLA-4
cells were mock, TRIM, or LAX transfected and stimulated with anti-CD3-
coated beads for the indicated periods of time. The cells were then fixed, per-
meabilized, and stained with anti-CTLA-4 –Alexa 568 and anti--tubulin–
Alexa Fluor 488. The cells were analyzed by confocal microscopy (CTLA-4,
red; MTOC [microtubules], green). Bar, 10 m. A cell was considered positive
for MTOC reorientation if its MTOC was juxtaposed to a bead in contact with
the cell (upper panel). Cells with polarized MTOC toward the cell-bead con-
tact area of 3 m were counted. The histogram shows the percentages of cells
with reoriented MTOC stimulated for the indicated time points (n  2; 50 to
70 cells/sample).
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We previously reported that CTLA-4 also interacts with TRIM,
another type 1 transmembrane adaptor that is immune cell spe-
cific and whose downregulation impaired the expression of
CTLA-4 (22). LAX therefore shares with TRIM a role in the early
stage of TGN-derived CTLA-4-containing vesicle formation for
transport to the cell surface. However, in contrast, LAX was able to
bind to both TRIM and CTLA-4 in a specific manner. For exam-
ple, it did not bind to LAT or CD28 in coexpression and copre-
cipitation assays. LAX differed from TRIM in that it had the bind-
ing properties of a central coordinator of the CTLA-4 transport
process. It had the unusual ability to bind directly to Rab8 in
addition to CTLA-4 and TRIM, as seen by coexpression in non-
lymphoid cells. Rab8 is a key marker for vesicle trafficking from
the TGN to the plasma membrane. This observation, together
with the binding of LAX to TRIM and CTLA-4, suggests that it can
operate as a coordinator in the formation of a complex for proper
CTLA-4 transport to the plasma membrane (Fig. 9).
Increased CTLA-4 expression by LAX in turn led to increased
inhibition of IL-2 production by anti-CD3/CTLA-4 coligation. In
accordance with the reported role of LAX in the inhibition of
T-cell activation (36), LAX expression reduced IL-2 production
by ca. 30%, part of which may be related to increased CTLA-4
expression. However, at the same time, the combined effects of
LAX and anti-CD3/CTLA-4 inhibited IL-2 production by more
than 80%. This was in keeping with the ability of LAX to increase
CTLA-4 expression on 85% of cells, which is unprecedented in
the literature. Our data therefore show that while LAX can exert a
partial effect on TCR signaling, it cannot account for the more
robust inhibition seen with the increased level of CTLA-4 expres-
sion and inhibition on T cells. These findings show that LAX can
exert a discrete inhibitory effect on T-cell activation by regulating
the expression of CTLA-4 on the surfaces of cells. Further, T cells
from LAX knockout mice were hyperstimulated by anti-CD3 via
an unknown mechanism. Our data suggest that the loss of LAX
may exert its effect by reducing CTLA-4 expression and thus pre-
disposing T cells to increased activation due to the absence of the
negative regulator (36).
In accordance with the well-established role of Rab8 in modu-
lating polarized membrane transport through the reorganization
of actin and microtubules to cell surfaces (48, 49), LAX expression
was found to modulate the polarization of the MTOC and
CTLA-4 to the contact regions of T cells with anti-CD3-coated
beads. This therefore provides a potential molecular basis to ex-
plain the previous observation that CTLA-4 polarizes toward the
sites of TCR engagement and immunological synapse of T cells
(23, 56). During antigen presentation, the MTOC reorients itself
from the trailing region of the cell to the area between the nucleus
and the TCR contact region. The Rab8/LAX pathway is likely to
mediate the directional release since overexpression of LAX en-
hanced the reorientation of the MTOC and the polarized release of
CTLA-4 to the contact site on anti-CD3-coated beads. It is unclear
in the literature whether the formation of vesicles can influence
the signals that induce the reorientation of the MTOC for the
polarized release of intracellular molecules. The ability of LAX to
facilitate the reorientation of the MTOC would be compatible
with this interpretation or the possibility that LAX independently
affects the MTOC by other mechanisms. In either case, the com-
bined effects of increased CTLA-4/LAX/Rab8 complex formation,
and the enhanced polarization of the MTOC would act to facilitate
the optimal release of CTLA-4 to the surfaces of cells.
Overall, our results identified a novel Rab8-LAX complex that
mediates CTLA-4 transport to the surfaces of T cells. Future work
will be needed to determine whether this pathway operates in
conjunction with other signaling events. For example, CTLA-4,
TRIM, and LAX all possess an YXXM-binding motif for PI3K. A
report by Simonsen et al. highlights the importance of coregula-
tion between Rab family GTPases and phosphoinositides (59).
Activated Rab5 on endocytosed vesicles recruits phosphatidylino-
sitol-3-phosphate [PtdIns(3)P], whereas Rab8 recruits PtdIns(4)P at
the TGN and secretory vesicles by regulating the phosphoinositide
phosphatase OCRL (oculocerebrorenal syndrome of Lowe) (60).
Both Rab family GTPases and phosphoinositides are needed for
the polarized transport of secretory vesicles (61, 62). Further, it
was recently shown that p85 of PI3K binds and regulates the phos-
phatase PTEN (phosphatase and tensin homologue), providing a
link from PI3K to OCRL (63).
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